drugset / Trial / NCT05277051
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Timeline
- Start
- 2022-03-22
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belrestotug | Monoclonal antibody | — | — |
| Subject | Dostarlimab | Monoclonal antibody | — | — |
| Subject | HS-20093 | Other / unclassified | — | — |
| Subject | Nelistotug | Monoclonal antibody | — | — |
| Subject | Remzistotug | Monoclonal antibody | — | — |